The company announced the successful completion of its first human clinical trial for its Continuous Blood Glucose Monitor (CBGM), a device that could eliminate both the accuracy limitations of ...

Other factors that can limit the accuracy of both CGM and CBGM values include inter-individual differences in the uptake and absorption of glucose after consuming a meal, blood flow differences ...

RUTHERFORD, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and ...

Glucotrack’s Medical Advisory Board provides strategic guidance to Glucotrack as the Company advances development of its innovative CBGM system, which is designed to directly measure ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the ...

today announced that updated preclinical data for its continuous blood glucose monitor (“CBGM”) will be presented at the 24th An Biotech veteran joins Glucotrack’s Board to support bringing ...